In an attempt to produce substantial reductions in pulmonary arterial pressure and pulmonary vascular resistance in patients with primary pulmonary hypertension, a new treatment strategy using high doses of calcium channel-blocking drugs was developed. Thirteen patients were given an initial test dose of 60 mg diltiazem or 20 mg nifedipine followed by consecutive hourly doses until a 50% fall in pulmonary vascular resistance and 33% fall in pulmonary arterial pressure was achieved or untoward side effects developed. The initial drug challenges failed to produce significant reductions in mean pulmonary arterial pressure or pulmonary vascular resistance. In eight of 13 patients, continued hourly doses produced a reduction in mean pulmonary arterial pressure of 48% (61 to 35 mm Hg, pK<.01) and a reduction in pulmonary vascular resistance of 60% (15 to 6 units, p<.01). These patients were discharged on high-dose (up to 720 mg/day diltiazem or 240 mg/day nifedipine) calcium channel-blocking drugs as long-term therapy. Five patients have returned for restudy after 1 year. In four of five the reductions in pulmonary arterial pressure and pulmonary vascular resistance were sustained and were associated with regression of right ventricular hypertrophy as assessed by electrocardiography and echocardiography. One patient who reduced her dose to a conventional level had a return of her pulmonary arterial pressure and pulmonary vascular resistance toward previous levels. We conclude that substantial reductions in pulmonary arterial pressure and pulmonary vascular resistance that are associated with regression of right ventricular hypertrophy are possible in some patients with primary pulmonary hypertension by use of calcium channel-blocking drugs. High doses of these drugs were required to produce marked hemodynamic responses in patients who exhibited marginal responses to conventional doses. In patients able to tolerate the high-dose therapy sustained reductions in pulmonary arterial pressure and pulmonary vascular resistance appear to last for a period of at least 1 year.
SINCE Rubin and Peter' reported a 52% reduction in pulmonary vascular resistance from hydralazine in 4 patients with primary pulmonary hypertension (PPH) in 1980, there have been several published studies on potential beneficial and adverse effects of vasodilators for PPH. 24 In contrast to their effectiveness in lowering systemic pressure in patients with essential hypertension, however, vasodilators have not generally produced a substantial reduction in pulmonary arterial pressure in those with PPH. 1-6 In addition, there have been no reported series providing hemodynamic data Vol. 76, No. 1, July 1987 on long-term (greater than 1 year) follow-up in patients who appear to respond favorably.
Based on the contention that a substantial reduction in pulmonary arterial pressure must accompany the fall in pulmonary vascular resistance in order for patients with PPH to have sustained improvement,7'8 we undertook this study using high doses of calcium channelblocking drugs in patients with PPH to see if we could produce greater reductions in pulmonary pressure than previously achieved with conventional treatment. In addition, patients who appeared to respond favorably were followed with a repeat right heart catheterization after 1 year to assess long-term efficacy.
were enrolled in the study (reviewed and approved by the University of Illinois Institutional Review Board). There were 10 women and three men (mean ages 36 + 12 years). All of the patients fulfilled the diagnostic criteria for PPH based on history, physical examination, chest radiograph, lung scan, pulmonary function testing, two-dimensional echocardiography, and absence of either left-to-right shunting or elevated left heart pressures on catheterization, according to the protocol of the National Institutes of Health PPH Registry. 9 A diagnostic right heart catheterization was performed in all of the patients after an overnight fast, and all medications except for digoxin and diuretics had been discontinued at least 2 weeks prior to the study. No patient was treated with anticoagulants, either before or after this protocol. Systemic and pulmonary arterial pressures were measured and cardiac outputs were determined by the thermodilution technique, with values for pulmonary vascular resistance and systemic vascular resistance calculated according to standard formulas. The patients were then transferred to the coronary care unit with a thermodilution flow-directed catheter in the pulmonary artery and a small arterial cannula in the femoral artery for further drug evaluation. Short-term drug protocol. The patients were allowed 2 to 4 hr to become acclimated to the cardiac care unit surroundings before the drug study was initiated, with measurements of systemic and pulmonary pressures and cardiac outputs made periodically until stable baseline values were achieved, and then hourly throughout the period of drug evaluation. All patients received an initial challenge of a conventional dose of nifedipine (20 mg) or diltiazem (60 mg) and hemodynamic measurements were made after 1 hr. Consecutive oral doses of either nifedipine or diltiazem were then administered hourly to the patients until a "break" or positive response (defined as a 50% reduction in pulmonary vascular resistance and a 33% fall in mean pulmonary arterial pressure) was obtained, or until the patient experienced adverse effects of the drug requiring its discontinuation. For purposes of this study, 20 mg nifedipine and 60 mg diltiazem were considered to be equivalent oral doses. If there was no response to multiple consecutive doses of diltiazem, nifedipine was used in an attempt to minimize side effects while maintaining additive effects with respect to calcium-channel blockade. Drug challenges were stopped if the systemic systolic blood pressure fell below 90 mm Hg (one patient), or if gastrointestinal upset precluded further drug administration (four patients).
In patients in whom a positive response was achieved the cumulative dose of drug deemed effective was then readministered every 6 to 8 hr (depending on the duration of action) over a 24 hr period. If a single large dose produced marked side effects, however, the dose was reduced and given more frequently. For example, if it were determined that nifedipine was effective as 80 mg every 8 hr but produced marked nausea, the dose would be changed to 60 mg every 6 hr or 40 mg every 4 hr so that the total daily dose administered (in this case 240 mg) remained constant. Final hemodynamic measurements were made 1 hr after the last dose.
Long-term follow-up. Patients having a positive response were discharged on the drug regimen that was deemed effective. To minimize side effects, some patients were started on lower doses (20 mg tid nifedipine or 60 mg tid diltiazem), and then the dose was titrated gradually upward over 6 weeks until the previously determined effective daily dose was reached. In addition, digoxin was initiated to counteract any negative inotropic effects of the calcium blockers. After 1 year the patients were to return and undergo repeat electrocardiography, two-dimensional echocardiography, and right heart catheterization. The catheterization was done on an outpatient basis in the cardiac catheterization laboratory 1 to 2 hr after the last dose of drug was administered.
Statistical analysis. Means and standard deviations were computed for the variables measured. Comparisons between control and treated states were made by paired Student's t test.
Differences between the effect of conventional doses and high doses of drug were evaluated with McNemar's test. Comparisons between responders and nonresponders were made by student's t test for unpaired data.
Results
The clinical characteristics of hemodynamic findings in the 13 patients studied are listed in tables 1 and 2. All of the patients had marked elevations in pulmonary arterial pressure (61 ± 15 mm Hg) and pulmonary vascular resistance (16 ± 7 U), which are characteristic of primary pulmonary hypertension. After a conventional test dose of either 60 mg diltiazem or 20 mg nifedipine there was a mean 2% (p= NS) fall in pulmonary pressure and a 3% (p = NS) fall in pulmonary vascular resistance. Further hourly dosing however, produced a mean 36% fall in pulmonary arterial pressure and a 49% fall in pulmonary vascular resistance in eight of the 13 patients (figures 1 and 2). No significant change occurred in heart rate (from 82 to 83 beats/min), indicating that the increased cardiac output was due to an increase in stroke volume. The dose required to "break" the pulmonary arterial pressure was then readministered every 6 to 8 hr, with the effects of the therapy noted to be sustained for 24 hr in all responding patients. In those in whom the drug challenge failed, either because of systemic hypotension or other adverse drug effects (nausea, vomiting, and agitation), the maximum change obtained was a 5% fall in mean pulmonary pressure and a 12% fall in pulmonary vascular resistance, compared with a 48% fall in pulmonary arterial pressure (p<.01) and a 60% fall in pulmonary vascular resistance (p<.01) in the responders after 24 hr. The nonresponders had a fall in RESPONDERS NON -RESPONDERS mean systemic arterial pressure of 22%, compared with a 12% reduction in the responders (p<.05). In the responders, a "break" in the level of pulmonary arterial pressure occurred after three consecutive hourly doses in two patients, four consecutive doses in three patients, seven consecutive doses in two patients, and 10 consecutive doses in one patient. In the nonre- The effect of the treatment regimen on pulmonary vascular resistance, with the patients divided as responders and nonresponders. In the responders all but one had a reduction in pulmonary vascular resistance to 7 Wood units or less with high-dose therapy. sponders, a lack of response and/or untoward effects of therapy were noted after 9 consecutive hours of treatment in one patient, 1 1 hr in one, and 12 hr in the other two (table 1) untarily reduced her dose from 240 to 120 mg diltiazem/day.) Each patient noted an improvement in symptoms, with every patient but one (see below) improving by at least one New York Heart Association (NYHA) functional class and all patients falling into NYHA functional class I or II. In addition, in each there was an improvement in the electrocardiographic manifestations of right ventricular hypertrophy, ranging from a reduction in right-axis deviation and R wave voltage in lead V1 to normalization of the electrocardiogram (table 3; figure 3 ). All had improvement on their echocardiograms, with four of five showing a return to virtual normal cardiac chamber size and normal septal systolic curvature (table 3; figure 4 ).
The hemodynamic findings after 1 year of therapy are listed in table 2. In four of the five patients the reduction in pulmonary arterial pressure and pulmonary vascular resistance achieved over the initial 24 hr of treatment was sustained for 1 year. In one patient (No. 2) however, there appeared to be a return of pulmonary arterial pressure and pulmonary vascular resistance toward the values recorded 1 year before. Although she reported an improvement in functional class and lifestyle, she had the least change noted in her noninvasively measured variables as well. The two responding patients who have been followed for less than 1 year have also reported a sustained improvement in symptoms; of the nonresponding patients, the conditions of two are unchanged, those of two have deteriorated, and one has died. . The two-dimensional echocardiograms obtained from the parasternal short-axis view before drug treatment and after 1 year in patient 1. In addition to the reduction in right ventricular chamber size there was a restoration of the septal curvature during systole from a reversed to a normal configuration indicative of a reduction in right ventricular systolic pressure. 25 One patient who responded to the high-dose calcium-blocker regimen has died. By agreement she was to return to Chicago for a follow-up study after 1 year, although her follow-up status was kept by phone each month. After 6 months she and her referring physician stated that she had become completely symptom free. She then presented with abdominal pain and vomiting that was, in retrospect, likely due to viral gastroenteritis. However, the referring physician, uncomfortable with the amount of nifedipine she was taking, believed her symptoms possibly due to the drug and reduced her daily dose from 160 to 40 mg over a short term. Two weeks later she presented with severe right heart failure and died. A right heart catheterization performed before her death showed severe pulmonary hypertension with suprasystemic pressures.
Discussion
Much uncertainty has arisen about the definition of a beneficial response to vasodilator treatment in patients with PPH. Therapy of essential hypertension has used a reduction in blood pressure toward normal levels as a measure of effectiveness. Studies on PPH, however, have generally regarded reductions in pulmonary vascular resistance of 20% as indicative of a favorable response.8'`However, when the effects of long-term vasodilator therapy were evaluated in patients with PPH who achieved a 20% fall in pulmonary vascular Vol. 76, No. 1, July 1987 resistance there was no detectable influence of the treatment on clinical course or survival.8
In that previous study there was a mean fall in pulmonary arterial pressure of only 3.5% with conventional doses of nifedipine or hydralazine. In this study the dose of calcium-channel blockers administered was considerably higher, and was titrated to the patients' hemodynamic response. Had these patients been limited to a conventional drug challenge their responses would have also shown a minimal fall in pulmonary pressure and pulmonary vascular resistance similar to that in previously published trials. By administering high doses of calcium-channel blockers reductions in pulmonary arterial pressure of 48% and in pulmonary vascular resistance of 60% were achieved in 62% (eight of 13) patients without causing systemic hypotension. We have previously noted that spontaneous changes in pulmonary hemodynamics could result in a lowering of pulmonary arterial pressure by as much as 22%." The magnitude of changes observed in this trial, however, make it unlikely that spontaneous variability was responsible for these results.
Although the large fall in mean pulmonary arterial pressure and pulmonary vascular resistance seen was encouraging, it was felt that demonstration of longterm drug efficacy was necessary in order for these findings to be truly meaningful. For that reason we have chosen to wait 1 year until some follow-up hemodynamic studies could be performed to evaluate our treatment. In four of the five patients restudied there occurred a sustained reduction in both pulmonary arterial pressure and pulmonary vascular resistance that was associated with regression of right ventricular hypertrophy documented by electrocardiography, a reduction in right ventricular cavity size documented by echocardiography, and a return to a nornal, symptomfree lifestyle. In one patient, the short-term effects of the treatment were not sustained, although she did not differ from the other responders with respect to the baseline level or magnitude of reduction in pulmonary arterial pressure or pulmonary vascular resistance. She did, however, complain of drug side effects (primarily leg edema and dizziness) that resulted in a reduction in the previously determined "effective" dosage.
Data from the five patients who failed to respond to the high-dose drug challenge were also analyzed. These patients did not differ from the responders with regard to their ages, duration of symptoms, baseline level of pulmonary arterial pressure, or pulmonary vascular resistance. Rather, they differed only in the inability of drug challenge to substantially lower their pulmonary arterial pressures or in the development of untoward side effects.
Substantial reductions in pulmonary arterial pressure in patients with PPH have been noted in several case reports by other investigators using a variety of vasodilators, including the calcium-channel blockers. 2 These patients responded to conventional doses of the drugs used, suggesting that their disease was less advanced. That the initial mean pulmonary arterial pressure was generally less than 50 mm Hg would support this. Had we limited our assessment of drug efficacy to conventional testing, however, none of our responding patients would have been placed on long-term therapy.
The reason for the apparent selective pulmonary effects of the calcium-channel blockers in the responders is not obvious. However, it has been shown that calcium-channel blockers reduce systemic arterial pressure in patients with essential hypertension but not in normal controls20 and relieve coronary artery spasm in patients with Printzmetal's angina while having little effect on either systemic and pulmonary pressures.2`Thus, it appears that, rather than being selective for a specific arterial bed, calcium-channel blockers work selectively on vascular smooth muscle that has heightened tone and is vasoconstricted, leaving the other vasculatures largely unaffected. That we required large doses of calcium-channel blockers in our patients with PPH suggests that there is a different sensitivity of the vascular beds or disease states to the effects of calcium-channel blockade. The nonresponders probably have vascular changes that are too advanced to permit pulmonary vascular smooth muscle relaxation and vasodilation. 22 The drop in systemic arterial pressure in these patients after the very high doses of calcium-channel blockers may be related to both direct effects on systemic vascular tone and other effects that the calcium-channel blockers can have on blood pressure through antisympathetic actions at aadrenergic receptors.23
That we have not seen the adverse responses noted by Packer et al.,24 who administered nifedipine for PPH, we believe is due to the magnitude of the reduction in pulmonary arterial pressure we noted, which would offset the negative inotropic properties of the drug. In addition, we administered digoxin to all of these patients, although whether this makes a difference clinically is speculative. Finally, the mean right atrial pressures of the patients in Packer's series were considerably higher than those of our patients, suggesting they had considerable impairment of right ventricular function. In any case, caution must still be emphasized when administering calcium-channel blockers to any patient with PPH.
The patient who responded favorably to the highdose calcium channel-blocker regimen but then died after the reduction in her therapy 6 months later also supports the notion that active pulmonary vasoconstriction is occurring in these patients. Rebound pulmonary hypertension has been reported on the cessation of vasodilator drugs by others,'6' 19 and should serve to caution physicians against the sudden withdrawal of therapy in these patients. We conclude that sustained reductions in pulmonary arterial pressure and pulmonary vascular resistance that are associated with regression of right ventricular hypertrophy are possible in some patients with PPH by use of calcum channel-blocking drug therapy. The response to conventional doses appears inadequate, however, to identify those patients in whom these effects are possible with higher doses. The testing of high doses of calcium-channel blockers should be done only with direct hemodynamic monitoring to watch for adverse hemodynamic effects, be it systemic hypotension or increasing right atrial pressure. Further studies are also needed to determine why some patients benefit whereas others do not. In addition, whether patients with pulmonary hypertension as a result of other forms of obstructive pulmonary vascular disease will respond similarly remains untested.
That the reductions in pulmonary pressure and resistance have been maintained for 1 year leads us to cautious optimism about the medical management of patients with PPH. Whether or not those patients exhibiting this response to high-dose calcium-channel blockade will maintain these effects for periods longer than 1 year can only be answered by continued longterm follow-up.
